Himalaya Nutravedics India IPO Opens on September 22
Himalaya Nutravedics India IPO will open for subscription on September 22 and close on September 24, 2026. The BSE SME book-built issue comprises 24.996 lakh fresh shares and is priced at ₹100–₹106 per share. The total issue size is ₹26.50 crore.
| Particular | Details |
|---|---|
| IPO Name | Himalaya Nutravedics India IPO |
| IPO Dates | Sep 22–24, 2026 |
| Price Band | ₹100–₹106 |
| Issue Size | ₹26.50 Cr |
| Issue Type | Fresh Issue |
| Shares Offered | 24.996 Lakh |
| Lot Size | 1,200 Shares |
| Minimum Investment | ₹2,54,400 |
| Listing Platform | BSE SME |
| Allotment | Sep 25, 2026 |
| Refund | Sep 28, 2026 |
| Demat Credit | Sep 28, 2026 |
| Listing | Sep 29, 2026 |
| Lead Manager | Nirbhay Capital Services |
| Registrar | KFin Technologies |
Himalaya Nutravedics India IPO GMP Today
The latest available GMP indication for Himalaya Nutravedics India IPO is ₹0. Based on the upper price band of ₹106, the unofficial indicative price is therefore around ₹106. GMP is an unofficial and unregulated indicator and can change before listing.
| GMP Particular | Latest Update |
|---|---|
| GMP | ₹0 |
| Upper Price Band | ₹106 |
| Indicative Price | ₹106 |
| Indicative Premium | 0% |
Himalaya Nutravedics India Business Overview
Himalaya Nutravedics India is a Hyderabad-based company engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations. It also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical businesses.
Its product portfolio includes softgel and hardgel capsules, tablets, liquid orals, medicated oils and protein powders. The products cover areas such as maternal health, fertility, bone and joint care, metabolic health, paediatrics, urology and general wellness.
The company combines its own branded products with contract manufacturing, giving it exposure to both direct product sales and business-to-business manufacturing.
Himalaya Nutravedics India IPO Financial Performance
The company reported strong growth in FY2026. Revenue increased from ₹14.43 crore in FY2024 to ₹21 crore in FY2025 and ₹43.07 crore in FY2026. Profit after tax also increased from ₹0.43 crore in FY2024 to ₹2.23 crore in FY2025 and ₹7.39 crore in FY2026.
| Financial Year | Revenue | PAT |
|---|---|---|
| FY2024 | ₹14.43 Cr | ₹0.43 Cr |
| FY2025 | ₹21.00 Cr | ₹2.23 Cr |
| FY2026 | ₹43.07 Cr | ₹7.39 Cr |
FY2026 EBITDA was approximately ₹8.16 crore, with a reported EBITDA margin of about 18.82%.
Himalaya Nutravedics India IPO Financial Ratios
Himalaya Nutravedics India reported FY2026 net worth of approximately ₹16.38 crore and borrowings of around ₹5.13 crore. The reported RoNW was about 45.12%, while the debt-to-equity ratio was approximately 0.31.
| Financial Indicator | FY2026 |
|---|---|
| EPS – Pre Issue | ₹11.72 |
| Post-Issue P/E | ~12.63x |
| RoNW | 45.12% |
| ROE | 63.87% |
| ROCE | 36.41% |
| EBITDA Margin | 18.82% |
| PAT Margin | 17.16% |
| Debt-to-Equity | 0.31 |
Himalaya Nutravedics India IPO Fund Utilisation
The IPO proceeds are planned primarily for strengthening the company's working capital and expanding its marketing and sales activities.
| IPO Objective | Amount |
|---|---|
| Working Capital | ₹13.75 Cr |
| Branding, Digital Marketing & Sales Expansion | ₹7.50 Cr |
| General Corporate Purposes | Balance |
The planned deployment indicates a focus on supporting business growth, increasing brand visibility and meeting working-capital requirements.
Himalaya Nutravedics India Product Portfolio
The company manufactures and markets products across several Ayurvedic and nutraceutical categories. Softgel capsules were the largest reported product contributor in FY2026, followed by medicated oils and tablets.
Its manufacturing capabilities cover multiple dosage forms, while its portfolio includes both classical Ayurvedic formulations and proprietary formulations. The company also works with third-party customers for contract manufacturing.
Himalaya Nutravedics India IPO Growth Factors
The company has increased its revenue and profitability significantly over the reported three-year period. Its combination of branded products and contract manufacturing provides exposure to different customer segments.
The growing interest in Ayurvedic products, nutraceuticals and wellness products also provides a broader market opportunity. However, maintaining recent growth rates will depend on product demand, distribution expansion, marketing effectiveness and manufacturing execution.
Himalaya Nutravedics India IPO Risks
The company operates from a single manufacturing facility, which creates operational dependence on that location. It also does not have long-term contracts with all customers and suppliers, creating potential variability in business relationships.
Other factors to monitor include customer concentration, supplier dependence, working-capital requirements and competition in the Ayurvedic and nutraceutical markets.
As an SME-listed company, the shares may also experience lower trading liquidity and higher price volatility compared with mainboard-listed companies.
Himalaya Nutravedics India IPO Important Dates
The IPO is scheduled to open on September 22 and close on September 24, 2026. The basis of allotment is expected on September 25, refunds and demat credit are scheduled for September 28, and the proposed listing date is September 29.
| IPO Event | Date |
|---|---|
| IPO Opening | Sep 22, 2026 |
| IPO Closing | Sep 24, 2026 |
| Allotment | Sep 25, 2026 |
| Refund | Sep 28, 2026 |
| Demat Credit | Sep 28, 2026 |
| Listing | Sep 29, 2026 |
Himalaya Nutravedics India IPO Latest News Summary
Himalaya Nutravedics India IPO is scheduled to open tomorrow with a ₹100–₹106 price band and a total issue size of ₹26.50 crore. The company operates in the Ayurvedic and nutraceutical manufacturing segment, with both branded products and third-party contract manufacturing.
The latest reported GMP is ₹0. The company has also recorded significant revenue and profit growth, with FY2026 revenue of ₹43.07 crore and PAT of ₹7.39 crore. Investors can track GMP and subscription figures once bidding begins on September 22.
Disclaimer: IPO GMP is an unofficial and unregulated market indicator and may change at any time. Subscription data will be available only after bidding begins. This article is for informational purposes only and should not be considered investment advice.
Loading comments...